This suggests that, beyond the well-known STK11/KEAP1, alterations in other tumor suppressors like SMARCA4 (which often co-mutates with KRAS in smokers) and cell cycle regulators (CDKN2A loss) can also diminish the efficacy of KRAS inhibitors. Here, KRAS is linked to neoplasm.